Floatz logo

hh160

Gastroesophageal Adenocarcinoma

Huahui HealthPhase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
73/ 100

Competitive context

40 Active assets in the Gastroesophageal Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Eloxatin
Memorial Sloan Kettering Cancer Center
Phase 3BB
Pembrolizumab
Diwakar Davar
Phase 3BB
Nivolumab
Memorial Sloan Kettering Cancer Center
Phase 2BB
TRASTUZUMAB
UNICANCER
Phase 3BB
LENVATINIB
Merck Sharp & Dohme LLC
Phase 3B

View all 50 →

Same molecule, other indications

hh160 is also rated in:

small cell lung carcinomaDormant
CC
Indicative ·
41 / 100
View asset →
urothelial carcinomaDormant
C
Indicative ·
39 / 100
View asset →
hepatocellular carcinomaDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →